Topics

Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC

04:00 EDT 23 Jul 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its development and commercialization collaboration p...

Other Sources for this Article

Kristen K. Sheppard, Esq.
ir@akebia.com

NEXT ARTICLE

More From BioPortfolio on "Akebia Therapeutics Announces Submission of Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...